Phase 3 N=88 Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation
Kidney Transplantation
Primary: Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR) — 47; 46 ml/min — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=102 Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients
Heart Transplant Recipients
Primary: Peak Oxygen Consumption — 23.9; 22.0 ml/kg/min
Phase 3 N=71 A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.
Anemia
Primary: The Percentage of Participants Maintaining Average Haemoglobin (Hb) Concentration During the Efficacy Evaluation Period (EEP) Within the Target Range — 64.29; 57.14…
Phase 3 N=594 Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
Anemia in Chronic Kidney Disease in Non-dialysis Patients
Primary: Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to…
N/A N=441 Anemia Management in Chronic Kidney Disease Not on Dialysis Patients After the European Renal Best Practice (ERBP) Working Group Recommendations
ANEMIA
Primary: % Patients Achieving Target Hemoglobin Levels — 42.5; 35.3 percentage of participants
N/A N=90 Vitamin D Replacement After Kidney Transplant
Kidney Transplantation · Vitamin D Deficiency
Primary: Compare Efficacy and Safety of Two Vitamin D Supplements of These Doses in Normalizing Vitamin D Concentrations. — 8; 29 ng/ml
N/A N=290 An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant
Anemia, Kidney Transplantation
Primary: Percentage of Participants With a Hemoglobin Value of 11-12 Grams Per Deciliter (g/dL) From Visit 7 (Month 7) to Visit 9 (Month 9) — 20.7 percentage of participants
N/A N=655 Aortoiliac Stenosis in Kidney Transplantation
Aorto-Iliac Arterial Stenosis · Peripheral Arterial Disease · Kidney Transplant Failure
Primary: Patient Survival — 322; 48; 6 Participants
N/A N=2 Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
Multiple Myeloma · Amyloidosis
Primary: Number of Participants Without Renal Allograft Rejection at 6 Months Post-transplant — 1 Participants
Phase 2 N=22 Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease
Anemia · Chronic Kidney Disease · Chronic Renal Failure
Primary: Percentage of Participants Who Experienced Increase and Maintain Hemoglobin Levels (Two Consecutive Values) Greater Than or Equal to the Lower Limit of the Target Range…
Phase 3 N=756 Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Anemia in Chronic Kidney Disease Patients Not on Dialysis
Primary: Percentage of Participants in Receipt of 1 or More RBC Transfusions — 24.40; 24.14 Percentage of Participants
Phase 2 N=31 Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation
Kidney Transplantation
Primary: The Rate of Allograft Rejection — 0; 0 participants
Phase 2 N=12 Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection
Kidney Failure
Primary: Serum Creatinine Concentration — 112 umol/L
Phase 4 N=184 Treatment Response in Dialysis Anaemia
Anaemia · Haemodialysis
Primary: Haemoglobin Increase of Greater or Equal to 5g/l Following Receipt of Treatment — 53; 61 Participants
N/A N=60 Hyperglycemia in Renal Transplantation
Diabetes · End Stage Renal Disease
Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants
Phase 3 N=603 A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
Anemia
Primary: Median Time to First Cardiovascular Event — NA; NA days — p=0.2036
N/A N=338 Vascular Risk After Kidney Transplantation
Cardiovascular Disease · Chronic Kidney Disease · Diabetes
Primary: Carotid Intima Media Thickness (CIMT) — 0.044 millimeters (mm)
Phase 3 N=40 Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure
Anemia · Renal Failure
Primary: Hemoglobin Concentration at 6 Months — 117; 113 g/L
N/A N=50 Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant
Function of Renal Transplant
Primary: Calculated Estimated Glomerular Filtration Rate (eGFR) — 67.39; 80.48 ml/min/1.73m2 — p=0.32
Phase 3 N=836 Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
Anemia · End Stage Renal Disease (ESRD)
Primary: Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)] — 0.428; 0.193 g/dL — p=<0.001
N/A N=196 Survey on Anemia Therapy in Participants With Chronic Kidney Disease (CKD) Not on Dialysis
Chronic Kidney Diseases
Primary: Percentage of Participants by ESA Types at Baseline — 51.5; 17.3; 10.7; 20.4 percentage of participants
Phase 2 N=61 Bone Mass and Strength After Kidney Transplantation
End Stage Renal Disease · Kidney Transplantation · Bone Loss
Primary: Percent Change in Bone Density From Pre to Post-calcitriol Treatment Compared to Placebo as Assessed by Both Standard Methodologies — -0.81; -0.70 percent change
Phase 3 N=4 Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)
Anaemia
Primary: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 2; 1; 0 Participants
Phase 1 N=16 Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation
Kidney; Complications, Allograft
Primary: Baseline eGFR (Estimated Glomerular Filtration Rate) — 30.04; 30.04 mL/min/1.73 m2
Phase 2 N=5 Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
Kidney Transplantation · Kidney Failure, Chronic
Primary: Number of Participants Successfully Withdrawn Off of Immunosuppressant Medication for 104 Weeks — 3 participants
Phase 2 N=15 Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)
Anaemia
Primary: Percentage of Fractional Oral Iron Absorption Following Treatment With Daprodustat and rhEPO — 20.64; 20.62 Percentage (%) of iron absorbed — p=0.9971
Phase 3 N=2,964 Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
Anaemia · Aspergillosis, Allergic Bronchopulmonary
Primary: Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period: Non-inferiority Analysis…
N/A N=44 Low Dose Thymoglobin in Renal Transplant Patients
Acute Renal Failure
Primary: Rates of Acute Cellular Rejection Between Study Group — 4; 2 Number of rejection — p=<0.05
Phase 4 N=11 Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients
Renal Transplant Rejection · Transplants and Implants
Primary: Composite End Point of Acute Rejection, Graft Loss or Patient Death — 1; 1; 0; 0 participants
Phase 4 N=29 Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)
Kidney Transplant · Diabetes Mellitus, Type 2 · Diabetic Nephropathy
Primary: Freedom From Insulin Therapy Post Transplant — 3; 4 Participants